Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders: Regular article

Psychiatry and Clinical Neurosciences

Volumn 63, Issue 4, 2009, Pages 440-448

  Lai, Ying Ching ^a   Huang, Ming Chyi ^b,c   Chen, Chun Hsin ^c,d   Tsai, Chang Jer ^b   Pan, Chun Hung ^b   Chiu, Chih Chiang ^b,c,e  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Chinese; Conventional depot; Efficacy; Long acting risperidone; Pharmacokinetics

Indexed keywords

CHOLESTEROL; CLOPENTHIXOL DECANOATE; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; GLUCOSE; HALOPERIDOL DECANOATE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; AGED; ANXIETY; ARTICLE; ATTENTION DISTURBANCE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXCITEMENT; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTALKATIVE; INSOMNIA; MALE; MENSTRUAL IRREGULARITY; NAUSEA; NERVOUSNESS; NOSE CONGESTION; RACE DIFFERENCE; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 68149126465     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2009.01977.x     Document Type: Article

References (45)

1. Kane JM. Pharmacologic treatment of schizophrenia. Biol. Psychiatry 1999 46 : 1396 1408.
2. Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother. 2004 38 : 2122 2127.
3. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr. Scand. Suppl. 2000 407 : 83 86.
4. Simpson GM. A brief history of depot neuroleptics. Journal of Clinical Psychiatry 1984 45 : 3 4.
5. Kane JM, Aguglia E, Altamura AC, Ayuso GJL, Brunello N, Fleischhacker WW. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur. Neuropsychopharmacol. 1998 8 : 55 66.
6. Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics. Drugs 2003 65 : 493 512.
7. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr. Opin. Pharmacol. 2004 4 : 53 57.
8. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am. J. Psychiatry 2002 159 : 103 108.
9. Kane JM, Eerdekens M, Lindenmayer JP et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003 160 : 1125 1132.
10. Fleischhacker W, Eerdekens M, Karcher K. Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003 64 : 1250 1257.
11. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther. 2004 26 : 1994 2002.
12. Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 2004 1 : 91 100.
13. Turner M, Eerdekens E, Jacko M, Eerdedens M. Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int. Clin. Psychopharmacol. 2004 19 : 241 249.
14. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur. Psychiatry 2004 19 : 219 225.
15. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004 27 : 596 601.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington, DC, 1994.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972 18 : 499 502.
18. Wilkie A, Preston N, Wesby R. High dose neuroleptics: Who gives them and why? Psychiatr. Bull. 2001 25 : 179 183.
19. Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: Evidence from a routine therapeutic drug monitoring service. Ther. Drug Monit. 2005 27 : 103 106.
20. Bai YM, Chen TT, Lin WK, Chang WH, Wu B, Hung CH. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection. J. Clin. Psychopharmacol. 2007 27 : 306 308. (Pubitemid 46763318)
21. Wilson W. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J. Psychiatr. Pract. 2004 10 : 393 401.
22. Spina E, Avenoso A, Facciolà G et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001 153 : 238 246.
23. Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur. Neuropsychopharmacol. 2006 16 : 233 240.
24. Nesvåg R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr. Scand. 2006 114 : 21 26.
25. Lane HY, Chiu WC, Chang WH. Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels. J. Clin. Psychiatry 2000 61 : 209 214.
26. Lane HY, Chang WH. The role of the cytochrome P450 system in the metabolism of psychotropic drugs. Taiwanese J. Psychiatry 1997 11 : 345 356.
27. Chou WH, Yan FX, Robbins-Weilert DK et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 2003 49 : 542 551.
28. Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007 40 : 93 102.
29. Gefvert O, Eriksson B, Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol. 2005 8 : 27 36.
30. Remington G, Mamo D, Labelle A et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am. J. Psychiatry 2006 163 : 396 401.
31. Nyberg S, Farde L, Halldin C. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch. Gen. Psychiatry 1997 54 : 953 958.
32. Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: A cognitive perspective. Can. J. Psychiatry 2005 50 : 247 257.
33. Moller H-J, Llorca P-M, Sacchetti E, Stephen DM, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int. Clin. Psychopharmacol. 2005 20 : 121 130.
34. Akio H, Takehiko O. Evaluation of the clinical efficacy of risperidone for untreated and treated cases of schizophrenia from various aspects. Psychiatry Clin. Neurosci. 2005 59 : 556 562.
35. Desai NM, Huq Z, Martin SD, McDonald G. Switching from depot antipsychotics to risperidone: Results of a study of chronic schizophrenia. Adv. Ther. 1999 16 : 78 88.
36. Masand P. Using newer antipsychotic agents in primary care. Primary Psychiatry 1997 58 : 64 68.
37. Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin. Pharmacokinet. 1985 10 : 315 333.
38. Chang WH, Lin SK, Juang DJ et al. Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr. Res. 1993 9 : 35 40.
39. Conlon L, Fahy TJ, Toole RO, Gilligan J, Prescott P. Risperidone in chronic schizophrenia: A detailed audit, open switch study and two-year follow-up of patients on depot medication. Eur. Psychiatry 2002 17 : 459 465.
40. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. J. Clin. Psychopharmacol. 2008 28 : 210 213.
41. Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can. J. Psychiatry 2006 51 : 531 539. (Pubitemid 44166341)
42. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr. Res. 2004 70 : 1 17.
43. Wu RR, Zhao JP, Liu ZN et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006 186 : 572 578.
44. Lieberman J, Stroup T, Hsiao J. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005 353 : 1209 1223.
45. Lai YC, Chiu CC, Chen CH, Huang MC. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone. J. Clin. Psychopharmacol. 2007 27 : 523 524.